来那度胺致严重低血糖一例
本文报告一例74岁多发性骨髓瘤合并2型糖尿病女性,在来那度胺维持治疗约3年后发生3级低血糖(血糖35 mg/dl)。停用来那度胺后低血糖未再复发,Naranjo量表评分9分提示肯定相关,为首次报道的来那度胺致3级低血糖病例。
要点
- 来那度胺可能导致严重低血糖,尤其合并糖尿病者需警惕。
- 停用来那度胺后低血糖缓解,再暴露后低血糖复发支持因果关联。
- Naranjo评分9分提示来那度胺与3级低血糖为肯定相关。
核心结论
- 来那度胺可能引起3级低血糖,停用后低血糖缓解,再暴露后复发,Naranjo评分9分提示肯定相关。
研究设计与样本
- 单例病例报告:74岁女性多发性骨髓瘤合并2型糖尿病患者,来那度胺维持治疗后出现3级低血糖。
主要发现
- 患者来那度胺维持治疗约3年后出现顽固性低血糖,血糖35 mg/dl,需住院治疗。
- 停用来那度胺并排查其他原因后血糖改善,26天住院期间低血糖未复发。
- 出院前2天重新开始来那度胺,约1个月后因低血糖再次入院,最终永久停用来那度胺。
- 永久停用来那度胺后低血糖未再复发,1年内需重新启用降糖药物控制血糖。
- Naranjo不良反应概率量表评分为9分,提示来那度胺与3级低血糖为肯定相关。
关键数值与推荐
- 来那度胺相关低血糖此前仅在实体瘤I期试验中报告3例1级或2级低血糖,本例为首次报告的3级低血糖。
临床怎么用
- 使用来那度胺的患者,尤其合并糖尿病者,应监测血糖并警惕严重低血糖。
- 怀疑来那度胺相关低血糖时,应停用来那度胺并排查其他原因,再暴露需谨慎评估。
局限性
- 为单例病例报告,不能确立发生率或因果关系强度。
- 患者合并2型糖尿病且使用降糖药物,混杂因素可能影响判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is commonly used for multiple myeloma as either induction or maintenance therapy. The agent is associated with a host of adverse effects, but hypoglycemia has only been reported in one phase I trial in patients with solid tumors. We describe a 74-year-old woman who experienced grade 3 hypoglycemia (blood glucose level 35 mg/dl) likely related to lenalidomide. Her medical history was significant for refractory myeloma and type 2 diabetes mellitus. Lenalidomide was started as maintenance therapy following autologous bone marrow transplantation. Approximately 3 years later, she developed refractory hypoglycemia necessitating hospital admission despite stopping antihyperglycemic agents 4 weeks prior to admission. Lenalidomide was withheld during her admission and restarted 2 days prior to discharge. Work-up for causes of persistent hypoglycemia was negative, and her glucose levels improved over her 26-day hospitalization. She was readmitted approximately one month later for hypoglycemia, and lenalidomide was permanently discontinued. Again, work-up for causes of hypoglycemia was negative, and her glucose levels stabilized over her hospitalization. After discontinuation of lenalidomide, hypoglycemia did not recur, and within 1 year the patient required reinitiation of antihyperglycemic medications to control her glucose levels. Given the resolution of hypoglycemia with lenalidomide discontinuation and return of hyperglycemia after restarting the agent, it is likely that lenalidomide was the cause of the patient's hypoglycemia. Use of the Naranjo adverse drug reaction probability scale indicated a definite relationship (score of 9) between the patient's development of grade 3 hypoglycemia and lenalidomide therapy. Although this adverse drug reaction had been previously reported with lenalidomide during phase I trials in patients with solid tumors, only grade 1 or 2 hypoglycemia was reported in three patients. To our knowledge, this is the first reported case of grade 3 hypoglycemia caused by lenalidomide.
引用
- Przybylski DJ, Birhiray R, Reeves DJ, et al. Severe Hypoglycemia Caused by Lenalidomide. Pharmacotherapy. 2017. PMID: 29155440. doi:10.1002/phar.2061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。